CytoMed Therapeutics Limited (GDTC) AI Stock Analysis

• Market Cap: $24.17M
• Dividend Yield: N/A
• Average Volume (3M): 19.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.10
• Revenue Growth: N/A
• EPS Growth: -21.99%
• Country: US
• Employees: 43
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 11,733,712
• 10 Day Avg. Volume: 29,730
• 30 Day Avg. Volume: 19,046
• PEG Ratio: 0.46
• Price to Book (P/B): 5.97
• Price to Sales (P/S): 754.46
• P/FCF Ratio: -14.31
• Enterprise Value/Market Cap: 1.49
• Enterprise Value/Revenue: 139.40
• Enterprise Value/Gross Profit: 127.11
• Enterprise Value/Ebitda: -17.57
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: $2.00 ▼(-2.91% Downside)

The overall stock score reflects significant financial challenges, including declining revenues and cash flow deficits, which are the most impactful factors. Technical analysis provides some short-term optimism, but valuation concerns due to ongoing losses weigh heavily on the score.

CytoMed Therapeutics Limited Business Overview & Revenue Model

Company Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

How the Company Makes Money

CytoMed Therapeutics generates revenue through multiple streams, including the commercialization of its proprietary therapies and technologies, licensing agreements with pharmaceutical companies, and partnerships with research institutions. The company may receive upfront payments, milestone payments based on the progress of clinical trials, and royalties on sales from licensed products. Additionally, funding from government grants and collaborations with industry partners contribute to its financial stability. Significant partnerships with key players in the biotech industry also enhance its research capabilities and market reach, thereby driving further revenue growth.

CytoMed Therapeutics Limited Financial Statement Overview

Summary

The company faces significant financial challenges, with declining revenues, persistent losses, and cash flow deficits. Despite a strong equity position relative to debt, the need for improved cash management and revenue generation is critical.

Income Statement

The income statement reveals significant challenges, with the company experiencing a decline in total revenue from $290,560 in 2023 to $52,005 in 2024, indicating a negative revenue growth rate. Additionally, the net income remained negative, with a considerable net loss of $1,883,178 in 2024, reflecting poor profitability and a concerning net profit margin.

Balance Sheet

The balance sheet shows a strong equity position with stockholders' equity significantly outweighing total debt, resulting in a low debt-to-equity ratio. However, the reduction in total assets and stockholders' equity from 2023 to 2024 highlights potential risks and financial instability.

Cash Flow

The cash flow statement indicates negative operating cash flow, with a substantial free cash flow deficit of $2,742,350 in 2024. While the company had a significant capital expenditure in 2024, the free cash flow remains negative, pointing to cash management challenges and the need for more efficient cash utilization.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	258.16K	52.01K	290.56K	0.00	84.18K	44.92K
Gross Profit	283.14K	52.38K	381.92K	-81.03K	81.59K	41.43K
EBITDA	-2.05M	-1.79M	-2.94M	-1.10M	-1.05M	-776.21K
Net Income	-2.79M	-1.88M	-3.13M	-2.27M	-1.53M	-1.47M
Balance Sheet
Total Assets	6.57M	7.37M	9.37M	3.90M	4.51M	2.89M
Cash, Cash Equivalents and Short-Term Investments	2.25M	3.64M	6.82M	1.18M	1.87M	703.20K
Total Debt	385.05K	339.20K	339.50K	3.15M	2.42M	2.26M
Total Liabilities	892.51K	749.76K	852.28K	3.46M	2.59M	2.53M
Stockholders Equity	5.62M	6.57M	8.52M	438.24K	1.92M	360.37K
Cash Flow
Free Cash Flow	-2.24M	-3.01M	-2.72M	-1.40M	-1.70M	-828.43K
Operating Cash Flow	-1.79M	-1.98M	-2.68M	-1.04M	-1.27M	-643.14K
Investing Cash Flow	1.62M	494.59K	-2.11M	-353.37K	-610.72K	-371.94K
Financing Cash Flow	-50.50K	-33.36K	8.16M	793.25K	3.09M	1.44M

CytoMed Therapeutics Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.06
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDTC, the sentiment is Neutral. The current price of 2.06 is above the 20-day moving average (MA) of 2.02, above the 50-day MA of 1.94, and below the 200-day MA of 2.30, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 52.16 is Neutral, neither overbought nor oversold. The STOCH value of 47.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GDTC.

CytoMed Therapeutics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLNN	57 Neutral	$86.55M	―	-1738.36%	―	-35.29%	45.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GDTC	48 Neutral	$24.17M	―	-42.29%	―	―	-21.99%
VYNE	47 Neutral	$9.42M	―	-67.73%	―	-2.06%	64.86%
BRNS	47 Neutral	$54.87M	―	-53.78%	―	―	-5.42%
PYPD	41 Neutral	$32.10M	―	-312.77%	―	―	61.18%
TPST	39 Underperform	$45.60M	―	-322.57%	―	―	3.39%

CytoMed Therapeutics Limited Corporate Events

CytoMed Therapeutics Unveils Promising AML Therapy Research

On October 2, 2025, CytoMed Therapeutics Limited announced a significant advancement in their research collaboration with The University of Texas, MD Anderson Cancer Center. The publication of their preclinical study highlights the potential of CytoMed’s allogeneic γδ T cell therapy for treating acute myeloid leukemia (AML), marking a promising step forward in developing ‘off-the-shelf’ immunotherapy solutions. This development is expected to pave the way for further clinical trials in Southeast Asia, potentially offering new treatment options for patients with limited alternatives, thereby strengthening CytoMed’s position in the biopharmaceutical industry.

CytoMed Therapeutics Reports Increased Revenue Amidst Financial Challenges

On September 30, 2025, CytoMed Therapeutics Limited released its unaudited interim condensed consolidated financial statements for the six months ending June 30, 2025. The company reported a significant increase in revenue to S$155,887 compared to the previous year. However, the financial results also showed a comprehensive loss of S$2,269,263, reflecting ongoing challenges in the company’s financial performance. The announcement provides insights into the company’s operational challenges and financial health, which could impact its market positioning and stakeholder confidence.

CytoMed Therapeutics Expands into Auto-immune Diseases with Cord Blood Biotech

On August 28, 2025, CytoMed Therapeutics Limited announced the successful expansion of clinical-scale natural killer (NK) cells from cord blood units, marking a significant step in their strategic reorganization. The company plans to establish a new cord blood-derived biotech under LongevityBank Pte Ltd, which will focus on autologous therapies, while CytoMed will continue to develop allogeneic therapies. This move aims to create new revenue streams and growth opportunities, leveraging their recent acquisition of a licensed cord blood bank in Malaysia. The acquisition provides access to valuable cord blood resources, enhancing CytoMed’s capabilities in developing therapeutics for autoimmune diseases and cancers. The company also plans to spin off LongevityBank as a standalone entity, further expanding its market presence.

CytoMed Therapeutics Launches ATM Offering Program to Boost Growth

On August 18, 2025, CytoMed Therapeutics Limited announced the initiation of an At-the-Market (ATM) offering program through a sales agreement with R.F. Lafferty & Co., Inc. This agreement allows CytoMed to sell ordinary shares worth up to $4,304,945, with the proceeds intended for general corporate purposes, including business diversification, development initiatives, and potential acquisitions. The announcement highlights the company’s strategic move to enhance its financial flexibility and explore growth opportunities, potentially impacting its market positioning and stakeholder interests.

CytoMed Therapeutics Advances ANGELICA Trial to Dose Level 2

On July 21, 2025, CytoMed Therapeutics Limited announced the successful completion of Dose Level 1 in its first-in-human Phase I dose-escalation clinical trial, known as the ANGELICA Trial. This trial evaluates the safety and tolerability of CTM-N2D, a novel allogeneic therapy using gamma delta T cells for treating advanced solid and haematological malignancies. The company is now proceeding to Dose Level 2, marking a significant milestone in its efforts to develop affordable cancer treatments. This advancement underscores CytoMed’s commitment to addressing the limitations of existing CAR-T therapies and enhancing its position in the biopharmaceutical industry.